Analyst Tracker/Daniel Brennan

Daniel Brennan

Q: How accurate are Daniel Brennan's stock ratings?

About 62% of Daniel's ratings were profitable over a one-year hold, with an average return of +9.9% per rating, measured by 13Foresight from historical prices.

Q: How is Daniel ranked?

Daniel Brennan is ranked #520 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

TD Cowen

Wall Street Analyst

★★★★☆

#520

on 13Foresight · ranked by our own returns

61%

Success Rate

+9.1%

Average Return

46 of 76 calls profitable · +5.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 61% of Daniel Brennan's ratings turned a profit when each position was held for 1 year — averaging +9.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

144 Buy 64 Hold 0 Sell

Daniel's Stock Coverage 41 ratings · 2026-08-06

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
PACB Pacific Biosciences	Aug 06, 2026	BUY	Buy +228.3% avg upside 14 analysts	$3.00 130.73% Upside	·	·
WAT Waters	Aug 05, 2026	BUY	Strong Buy -1.7% avg upside 30 analysts	$475.00 18.80% Upside	+0.0%	·
RVTY Revvity	Aug 05, 2026	BUY	Buy -6.7% avg upside 23 analysts	$130.00 12.95% Upside	+0.0%	·
XGN Exagen	Aug 04, 2026	BUY	Strong Buy +90.9% avg upside 10 analysts	$10.00 50.35% Upside	·	·
SOPH SOPHiA GENETICS	Aug 04, 2026	BUY	Strong Buy +64.8% avg upside 8 analysts	—	·	·
ILMN Illumina	Jul 31, 2026	HOLD	Buy -12.5% avg upside 30 analysts	$210.00 5.06% Upside	-7.4%	·
GH Guardant Health	Jul 31, 2026	BUY	Strong Buy +0.7% avg upside 31 analysts	$210.00 28.77% Upside	+0.7%	·
MYGN Myriad Genetics	Jul 31, 2026	HOLD	Hold +464.5% avg upside 24 analysts	$4.00 26.99% Upside	+10.1%	·
ADPT Adaptive Biotechnologies	Jul 30, 2026	BUY	Strong Buy -3.1% avg upside 15 analysts	$28.00 13.82% Upside	-2.4%	·
AVTR Avantor	Jul 29, 2026	HOLD	Buy +15.5% avg upside 26 analysts	$15.00 12.27% Upside	-8.6%	·
NEO NeoGenomics	Jul 28, 2026	BUY	Strong Buy +8.2% avg upside 18 analysts	$19.00 20.85% Upside	+14.1%	·
TMO Thermo Fisher	Jul 23, 2026	BUY	Strong Buy +4.7% avg upside 38 analysts	$675.00 16.87% Upside	-1.3%	·
DHR Danaher	Jul 22, 2026	BUY	Strong Buy +5.8% avg upside 45 analysts	$236.00 18.19% Upside	+10.2%	·
TEM Tempus AI, Inc. Class A	Jul 15, 2026	BUY	Strong Buy +39.6% avg upside 21 analysts	$71.00 52.09% Upside	-18.4%	·
BRKR Bruker	Jul 15, 2026	HOLD	Buy +6.5% avg upside 22 analysts	$60.00 14.35% Upside	-12.7%	·
QGEN Qiagen	Jul 15, 2026	HOLD	Buy -0.1% avg upside 24 analysts	$44.00 4.92% Upside	+0.5%	·
NTRA Natera	Jul 15, 2026	BUY	Strong Buy -2.4% avg upside 26 analysts	$325.00 18.37% Upside	-1.0%	·
MDXH MDxHealth	Jul 15, 2026	BUY	Strong Buy +1337.0% avg upside 8 analysts	$1.00 130.65% Upside	+0.3%	·
PSNL Personalis	Jul 15, 2026	BUY	Strong Buy +10.5% avg upside 11 analysts	$18.00 33.06% Upside	-21.1%	·
TXG 10x Genomics	Jul 15, 2026	HOLD	Buy -26.1% avg upside 18 analysts	$47.00 0.94% Downside	+3.7%	·
BDSX Biodesix	Jul 15, 2026	BUY	Strong Buy +43.1% avg upside 8 analysts	$30.00 31.72% Upside	+4.0%	·
WGS GeneDx Holdings	Jul 15, 2026	BUY	Strong Buy +15.0% avg upside 9 analysts	$85.00 21.50% Upside	+7.2%	·
GRAL GRAIL Inc	Jul 15, 2026	BUY	Strong Buy -6.5% avg upside 8 analysts	$88.00 18.53% Upside	-0.2%	·
CAI Caris Life Sciences, Inc.	Jul 15, 2026	BUY	Strong Buy +68.6% avg upside 20 analysts	$30.00 82.42% Upside	-5.8%	·
ALMR Alamar Biosciences, Inc.	Jul 15, 2026	BUY	Strong Buy +11.2% avg upside 5 analysts	$34.00 19.94% Upside	-2.9%	·
A Agilent	May 27, 2026	BUY	Strong Buy +5.5% avg upside 33 analysts	$155.00 9.80% Upside	+21.5%	·
SERA Sera Prognostics	May 06, 2026	BUY	Strong Buy +274.3% avg upside 7 analysts	—	+16.0%	·
QTRX Quanterix	May 06, 2026	HOLD	Buy +409.7% avg upside 8 analysts	$4.00 6.43% Upside	+4.0%	·
NAUT Nautilus Biotechnolgy	Apr 28, 2026	BUY	Strong Buy +1136.5% avg upside 5 analysts	—	-62.3%	·
SEER Seer	Feb 26, 2026	BUY	Strong Buy +417.5% avg upside 5 analysts	—	+5.3%	·
BDX Becton Dickinson	Jul 14, 2025	HOLD	Buy +14.4% avg upside 25 analysts	$183.00 7.28% Upside	+10.9%	·
LAB Standard BioTools	May 06, 2025	BUY	Strong Buy +668.5% avg upside 8 analysts	$2.50 218.74% Upside	-8.5%	·
LULU Lululemon Athletica	Apr 27, 2023	BUY	Buy +68.6% avg upside 45 analysts	$525.00 325.14% Upside	-3.5%	·
VZ Verizon	Apr 26, 2023	BUY	Buy +8.2% avg upside 41 analysts	$45.00 3.17% Downside	+15.5%	·
MRVI Maravai Lifesciences Holdings	Oct 15, 2021	BUY	Strong Buy +122.2% avg upside 17 analysts	$62.00 867.20% Upside	-48.0%	·
TWST Twist Bioscience	Oct 14, 2021	BUY	Strong Buy -20.4% avg upside 14 analysts	—	-75.0%	·
CRL Charles River Labs	Aug 17, 2021	BUY	Strong Buy -13.9% avg upside 34 analysts	$465.00 78.44% Upside	-47.3%	·
MTD Mettler-Toledo	May 07, 2021	SELL	Buy -14.7% avg upside 18 analysts	$1139.00 19.91% Downside	-2.9%	·
IQV IQVIA Holdings	Apr 23, 2021	BUY	Strong Buy +2.9% avg upside 39 analysts	$275.00 16.46% Upside	-1.8%	·
ICLR Icon	Mar 01, 2021	BUY	Strong Buy +15.9% avg upside 26 analysts	$232.00 41.91% Upside	+33.7%	·
VCYT Veracyte	Nov 26, 2013	BUY	Strong Buy +10.3% avg upside 19 analysts	$16.00 65.31% Downside	-48.4%	·

🔒 36 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Daniel Brennan — Frequently Asked Questions

How accurate are Daniel Brennan's stock ratings?

Based on the calls 13Foresight could measure, about 62% of Daniel's ratings were profitable over a one-year hold, with an average return of +9.9% per rating, or +6.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Daniel ranked on 13Foresight?

Daniel Brennan is currently ranked #520 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Daniel cover?

Daniel most recently has ratings on PACB, WAT, RVTY, XGN, SOPH, ILMN, GH, MYGN, ADPT, AVTR, NEO, TMO and 29 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Daniel Brennan

Rating Distribution

Welcome to 13Foresight!